Cargando…

Prostate-Specific Antigen Nadir and Time to Prostate-Specific Antigen Nadir Following Maximal Androgen Blockade Independently Predict Prognosis in Patients with Metastatic Prostate Cancer

PURPOSE: To evaluate the influence of prostate-specific antigen (PSA) kinetics following maximal androgen blockade (MAB) on disease progression and cancer-specific survival in patients with metastatic, hormone-sensitive prostate cancer. MATERIALS AND METHODS: One hundred thirty-one patients with met...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Seok Young, Cho, Dae Sung, Kim, Sun Il, Ahn, Hyun Soo, Kim, Se Joong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Urological Association 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3460002/ https://www.ncbi.nlm.nih.gov/pubmed/23060997 http://dx.doi.org/10.4111/kju.2012.53.9.607

Ejemplares similares

Association of time to prostate-specific antigen nadir and logarithm of prostate-specific antigen velocity after progression in metastatic prostate cancer with prior primary androgen deprivation therapy
por: Teoh, Jeremy YC, et al.
Publicado: (2017)

Clinical Implications of Nadir Serum Prostate-Specific Antigen Levels After Transurethral Enucleation of the Prostate
por: Cheng, Yung-Ting, et al.
Publicado: (2022)

Biochemical recurrence after radical prostatectomy according to nadir prostate specific antigen value
por: Chung, Jae Hoon, et al.
Publicado: (2021)

The neutrophil-to-lymphocyte ratio at the prostate-specific antigen nadir predicts the time to castration-resistant prostate cancer
por: Iwamoto, Genta, et al.
Publicado: (2021)

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
por: Tomioka, Atsushi, et al.
Publicado: (2014)

The Importance of Time to Prostate-Specific Antigen (PSA) Nadir after Primary Androgen Deprivation Therapy in Hormone-Naïve Prostate Cancer Patients
por: Sasaki, Takeshi, et al.
Publicado: (2018)

Correction: Biochemical recurrence after radical prostatectomy according to nadir prostate specific antigen value
por: Chung, Jae Hoon, et al.
Publicado: (2022)

Impact of perioperative factors on nadir serum prostate‐specific antigen levels after holmium laser enucleation of prostate
por: Martos, Mary, et al.
Publicado: (2021)

The slope associated with nadir prostate‐specific antigen is prognostically significant in men with hormone‐sensitive prostate cancer after primary androgen deprivation therapy
por: Zhenhao, Zeng, et al.
Publicado: (2022)

Prostate-specific antigen nadir after high-dose-rate brachytherapy predicts long-term survival outcomes in high-risk prostate cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2016)

Association of Nadir Prostate-specific Antigen >0.5 ng/mL after Dose-escalated External Beam Radiation with Prostate Cancer-specific Endpoints
por: Sheth, Niki, et al.
Publicado: (2018)

Prostate-specific antigen nadir within 1 year of radiotherapy combined with hormone therapy predicts cancer-specific mortality and biochemical recurrence-free survival in prostate cancer patients
por: Cetin, Ilknur Alsan, et al.
Publicado: (2022)

Prostate‐specific antigen nadir within 12 months as an early surrogate marker of biochemical failure and distant metastasis after low‐dose‐rate brachytherapy or external beam radiotherapy for localized prostate cancer
por: Nishimura, Shuichi, et al.
Publicado: (2018)

Image Guided Hypofractionated Radiotherapy by Helical Tomotherapy for Prostate Carcinoma: Toxicity and Impact on Nadir PSA
por: Barra, Salvina, et al.
Publicado: (2014)

Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir
por: Anwar, Mekhail, et al.
Publicado: (2014)

Maximal androgen blockade for advanced prostate cancer
por: Mukha, Rajiv Paul, et al.
Publicado: (2010)

Hospitalization Decreases Serum Prostate-Specific Antigen Values Compared With Outpatient Values in Patients With Benign Prostatic Diseases
por: Yoon, In Seok, et al.
Publicado: (2013)

HOXB13 is co-localized with androgen receptor to suppress androgen-stimulated prostate-specific antigen expression
por: Kim, Sin Do, et al.
Publicado: (2010)

Maximal androgen blockade for the treatment of metastatic prostate cancer—a systematic review
por: Lukka, H., et al.
Publicado: (2006)

The Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage for Metastatic Prostate Cancer
por: Kiper, Ahmet, et al.
Publicado: (2005)

The leucocyte nadir, a predictor of chemotherapy efficacy?
por: Kvinnsland, S
Publicado: (1999)

Reaching the Nadir of Medication Overuse in Chronic Migraine
por: Onan, Dilara, et al.
Publicado: (2022)

Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy.
por: Theyer, G., et al.
Publicado: (1997)

Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies
por: Ben Jemaa , Awatef, et al.
Publicado: (2010)

Prostate specific antigen /
Publicado: (2001)

Relationship between two year PSA nadir and biochemical recurrence in prostate cancer patients treated with iodine-125 brachytherap
por: Franca, Carlos Antônio da Silva, et al.
Publicado: (2014)

Prostate-Specific Antigen fluctuation: what does it mean in diagnosis of prostate cancer?
por: Kim, Jun Seok, et al.
Publicado: (2015)

Prostate-specific antigen screening for prostate cancer: An old but never-ending story
por: Kim, Sun Il
Publicado: (2023)

Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy
por: Kim, Yejin, et al.
Publicado: (2016)

Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells
por: LIU, TIANCHENG, et al.
Publicado: (2012)

Can Prostate-Specific Antigen Kinetics before Prostate Biopsy Predict the Malignant Potential of Prostate Cancer?
por: Kim, Sang Jin, et al.
Publicado: (2015)

Impact of Androgen Receptor Activity on Prostate-Specific Membrane Antigen Expression in Prostate Cancer Cells
por: Sommer, Ulrich, et al.
Publicado: (2022)

Utility of Prostate-Specific Antigen Isoforms and Prostate Health Index in the Diagnosis of Metastatic Prostate Cancer
por: Raju, Govinda Nanjaiah Laxmana, et al.
Publicado: (2022)

The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer.
por: Fosså, S. D., et al.
Publicado: (1992)

Prostate-Specific Antigen Mass and Free Prostate-Specific Antigen Mass for Predicting the Prostate Volume of Korean Men With Biopsy-Proven Benign Prostatic Hyperplasia
por: Park, Tae Yong, et al.
Publicado: (2013)

Nadir PSA is a strong predictor of treatment outcome in intermediate and high risk localized prostate cancer patients treated by definitive external beam radiotherapy and androgen deprivation
por: Geara, Fady B., et al.
Publicado: (2017)

The performance characteristics of prostate-specific antigen and prostate-specific antigen density in Chinese men
por: Teoh, Jeremy YC, et al.
Publicado: (2017)

Prostate-Specific Antigen Kinetics Effects on Outcomes of Low-Volume Metastatic Prostate Cancer Patients Receiving Androgen Deprivation Therapy
por: Lin, Yen-Chi, et al.
Publicado: (2021)

Expression of androgen receptor and prostate-specific antigen in male breast carcinoma
por: Kidwai, Noman, et al.
Publicado: (2004)

Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL
por: Kashiwabara, Takeshi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_s62u6tclt7cfb72nmfvkq121r8